Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Fujifilm Completes Bio Production Facility in US, Aiming to Initiate Operations in Early 2018
April 19, 2017
- Ex-Takeda Exec Noguchi Becomes President of Celgene Japan
April 18, 2017
- Boehringer Japan Logs 14 Consecutive Years of Growth in Ethical Drug Sales
April 18, 2017
- Celgene Submits Biz Improvement Plan over Side Effect Reporting Violation
April 18, 2017
- Japan Hemophilia Market Likely to Expand to Nearly 70 Billion Yen in 2024: Fuji Keizai
April 17, 2017
- Takecab Most Promoted Drug in HP Market for 4th Month in February: Anterio
April 17, 2017
- Shionogi Files Japan NDA for Another Shire-Licensed ADHD Med
April 14, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Sales Rep and Doctor at Center of Xarelto Survey Scandal Conflict over “Patient Consent”
April 14, 2017
- Novo Japan Chalks Up Record Sales in 2016 on Tresiba, Victoza
April 13, 2017
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
- Takeda Strikes Microbiome Deal with Canada’s NuBiyota
April 12, 2017
- Kyorin Gains Rights to Merck’s OAB Med in Asia
April 12, 2017
- Japan Authorized Generic Market Projected to Reach 81.7 Billion Yen in 2020: Fuji Keizai
April 11, 2017
- Takeda Sells Actos, Other Long-Listed Brands to Teva JV
April 11, 2017
- Ethical Drug Sales Sag 11.3% in February: Crecon
April 11, 2017
- Sumitomo Dainippon Gives Bukwang Korean Rights for Lurasidone
April 11, 2017
- Santen Makes Strategic Investment in US Cell Therapy Technology Firm
April 10, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…